ReleVote

PLASMA Act

Bill Number
H.R. 1476
Origin Chamber
House
Congress
119th Congress, Session 1
Policy Area
Health
Status
Introduced
Latest Action
2025-02-21: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Last Updated
2025-12-05T22:09:02Z

Official Summary

Preserving Life-saving Access to Specialty Medicines in America Act or the PLASMA Act

This bill phases-in certain price adjustments for plasma-derived products under the Medicare prescription drug benefit's Manufacturer Discount Program.

Current law requires manufacturers of covered drugs under the Medicare prescription drug benefit to provide a 10% discount for covered drugs during the initial coverage phase (i.e., before a beneficiary reaches the out-of-pocket spending threshold) and a 20% discount during the catastrophic coverage phase (i.e., after a beneficiary reaches the out-of-pocket spending threshold). 

The bill phases-in discounts for plasma-derived products over several years, starting with a 1% discount in 2026 for both the initial and catastrophic coverage phases, and ending with a 10% discount beginning in 2030 for the initial coverage phase and a 20% discount beginning in 2032 for the catastrophic coverage phase.

Sponsor

Rep. Hudson, Richard [R-NC-9]

Cosponsors (5)

Rep. Davis, Donald G. [D-NC-1], Rep. Murphy, Gregory F. [R-NC-3], Rep. Peters, Scott H. [D-CA-50], Rep. Rouzer, David [R-NC-7], Rep. Knott, Brad [R-NC-13]

Recent Actions

Bill Versions

Related Bills